Home›Allergy & Immunology› Mitochondrial dysfunction shapes immune cell function across sepsis phases, review finds
Mitochondrial dysfunction shapes immune cell function across sepsis phases, review findsMitochondrial Function Shapes Immune Response During Sepsis
Frontiers in MedicinePublished August 21, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider mitochondrial immunometabolism as a conceptual framework, but recognize evidence is limited and not yet clinically actionable.
This is a systematic mini-review examining the role of mitochondrial immunometabolism in sepsis. The authors synthesize evidence on how mitochondrial bioenergetic dysfunction shapes immune cell function across the dynamic course of sepsis, including both hyperinflammatory and immunoparalytic phases. They also address mitochondrial quality-control mechanisms, such as mitophagy, dynamics, and biogenesis, which appear to have time- and cell-type-dependent effects rather than fixed protective or deleterious roles.
The review highlights that mitochondrial components, including mtDAMPs, mtDNA, mtROS, and cardiolipin, can activate the cGAS-STING pathway and the NLRP3 inflammasome, amplifying inflammation and driving organ injury. These pathways are proposed as a framework for understanding the association between mitochondrial dysfunction and immune cell dysfunction or organ failure, though causality is not established.
The authors note significant limitations, including limited evidence on the roles of mitochondrial quality-control mechanisms and knowledge gaps in temporal dynamics, cellular heterogeneity, and clinical translation. The review does not report specific effect sizes, patient populations, or safety data.
Clinically, the findings suggest that mitochondrial immunometabolism may guide stage- and endotype-specific interventions in sepsis, but this remains a conceptual framework rather than a proven therapeutic target. Given the early stage of evidence, clinicians should interpret these insights cautiously and await further research.
How this fits prior evidence
This mini-review extends prior coverage by linking mitochondrial dysfunction to immune cell dysfunction across sepsis phases, complementing earlier findings on sepsis-induced cardiomyopathy and neutrophil function. It also aligns with the prior note on FSP1 as an endogenous inhibitor of ferroptosis, as both highlight mitochondrial and metabolic pathways in sepsis pathophysiology. However, unlike the corticosteroid trial showing mortality benefit, this review offers no clinical intervention data, only a pathophysiologic framework.
This review looks at how mitochondria, the powerhouses of cells, affect the body's response to sepsis. Researchers found that mitochondrial issues change how immune cells behave throughout the illness. This happens in both early inflammatory stages and later periods where the immune system becomes less active.
Specific components like mtDAMPs and mtDNA can trigger pathways that increase inflammation and lead to organ injury. The study also noted that processes like mitophagy and biogenesis do not have a simple protective or harmful role; instead, their effects depend on the specific cell type and the timing of the infection.
Because this is a review of current knowledge, it highlights several gaps in our understanding. There is currently limited evidence on how mitochondrial quality control works over time. While these findings help scientists understand why organs fail during sepsis, more research is needed to turn these insights into specific medical treatments.
What this means for you:
Mitochondrial health plays a complex role in immune responses and organ damage during different stages of sepsis.
Common questions
What role do mitochondria play in sepsis?
Mitochondria affect how immune cells function throughout the course of sepsis. They influence both the hyperinflammatory phase and the immunoparalytic phase. When mitochondrial components like mtDAMPs or mtDNA are released, they can activate pathways that increase inflammation and cause organ injury.
Are there specific risks associated with mitochondria in sepsis?
The research shows that certain mitochondrial components can trigger the cGAS-STING pathway and NLRP3 inflammasome. These processes can amplify inflammation and drive organ damage. However, the study notes that many details regarding the timing and cell types involved are still being researched.
How does this research help doctors treat sepsis?
Understanding mitochondrial immunometabolism may eventually help doctors create treatments tailored to specific stages of sepsis. Because different stages of the illness require different responses, identifying how mitochondria behave at each stage could lead to more targeted medical interventions.
Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains a leading cause of mortality in critical care, and sepsis-associated multiple organ failure continues to defy effective therapy. Increasing evidence positions mitochondria at the interface of cellular bioenergetics and innate immune signaling, making mitochondrial immunometabolism a compelling framework for understanding sepsis pathophysiology. In this mini-review, we synthesize how mitochondrial bioenergetic dysfunction shapes immune cell function across the dynamic course of sepsis, from the glycolytic, oxidative phosphorylation (OXPHOS)-uncoupled state of the hyperinflammatory phase to the bioenergetic failure of the immunoparalytic phase. We examine the contested roles of mitochondrial quality-control mechanisms: mitophagy, dynamics, and biogenesis, in immune cell remodeling, and propose that their net effect follows a time- and cell-type-dependent pattern rather than a fixed protective or deleterious role. We further discuss how mitochondrial damage-associated molecular patterns (mtDAMPs), mitochondrial DNA (mtDNA), reactive oxygen species (mtROS), and remodeled cardiolipin activate the cGAS-STING pathway and the NLRP3 inflammasome and cross-regulate one another to amplify inflammation and drive organ injury. Integrating these themes, we highlight mitochondrial immunometabolic crosstalk between key immune cell subsets (macrophages, neutrophils, and lymphocytes) and the parenchymal cells of vulnerable target organs (heart, kidney, lung, and the gut–liver axis). Finally, we identify knowledge gaps spanning temporal dynamics, cellular heterogeneity, and clinical translation, acknowledge the limitations of the current evidence, and outline emerging therapeutic and monitoring strategies. Collectively, mitochondrial immunometabolism links immune cell dysfunction to organ failure and may guide stage- and endotype-specific interventions in sepsis.
